Henry Ford + MSU researchers granted $3M from NIH to study HPV-positive head-and-neck cancers

Mayo Clinic researchers develop first salivary gland regenerative biobank to combat chronic dry mouth

Mayo Clinic researchers have established the world’s first biobank of human salivary gland tissue-organoids to study chronic dry mouth, or xerostomia, an agonizing side effect of damaged salivary glands that affects millions.

May 23, 2025

Vol.51 No.20

Clinical Roundup

Pembro + standard-of-care improves survival in locally advanced head-and-neck cancer

An international clinical trial co-led by WashU Medicine found that the immunotherapy drug pembrolizumab (Keytruda) added to standard-of-care therapy improved survival for patients with locally advanced head-and-neck cancer.

May 02, 2025

Vol.51 No.17

Clinical Roundup

Chemo-immunotherapy approach shows potential benefit in advanced HPV-negative head-and-neck cancer

Researchers from the University of Chicago Medicine Comprehensive Cancer Center demonstrated the potential of a novel treatment approach including immunotherapy to treat advanced human papillomavirus-negative head-and-neck squamous cell carcinoma. More than half of study participants had 50% or more of their tumors shrink after receiving the immunotherapy drug nivolumab with chemotherapy, followed by response-adaptive chemo-radiation therapy.

March 14, 2025

Vol.51 No.10

Clinical

Survey reveals most Americans are uninformed about HPV
A vaccine can prevent cancer—most people don’t take it

Each year, nearly 14 million people in the U.S. contract human papillomavirus, a common, sexually-transmitted virus that can cause several cancers.

March 07, 2025

Vol.51 No.09

By Claire Marie Porter

Clinical Roundup

First FDA-approved robot-assisted microsurgery for head-and-neck cancer performed at Cedars-Sinai

Cedars-Sinai performed the first robot-assisted microsurgical head-and-neck cancer reconstructive surgery in the United States after the robot device received FDA approval for the procedure.

February 21, 2025

Vol.51 No.07

Clinical Roundup

Nivolumab demonstrates superiority over standard of care for head-and-neck cancer in phase III trial

The Groupe d’Oncologie Radiothérapie Tête Et Cou, also known as the Head and Neck Oncology and Radiotherapy Group or GORTEC, announced that the randomized phase III CheckMate -9KW/NIVOPOSTOP GORTEC 2018-01 trial evaluating nivolumab (Opdivo) as a post-operative treatment component for resected patients with locally advanced squamous cell carcinoma of head and neck with high risk of relapse met its primary endpoint of disease-free survival across all comers.

January 17, 2025

Vol.51 No.02

Henry Ford + MSU researchers granted $3M from NIH to study HPV-positive head-and-neck cancers

YOU MAY BE INTERESTED IN

Mayo Clinic researchers develop first salivary gland regenerative biobank to combat chronic dry mouth

Pembro + standard-of-care improves survival in locally advanced head-and-neck cancer

Chemo-immunotherapy approach shows potential benefit in advanced HPV-negative head-and-neck cancer

Survey reveals most Americans are uninformed about HPV
A vaccine can prevent cancer—most people don’t take it

First FDA-approved robot-assisted microsurgery for head-and-neck cancer performed at Cedars-Sinai

Nivolumab demonstrates superiority over standard of care for head-and-neck cancer in phase III trial

Renew today!

Subscriber content

Never miss an issue!

Login

Henry Ford + MSU researchers granted $3M from NIH to study HPV-positive head-and-neck cancers

YOU MAY BE INTERESTED IN

Mayo Clinic researchers develop first salivary gland regenerative biobank to combat chronic dry mouth

Pembro + standard-of-care improves survival in locally advanced head-and-neck cancer

Chemo-immunotherapy approach shows potential benefit in advanced HPV-negative head-and-neck cancer

Survey reveals most Americans are uninformed about HPVA vaccine can prevent cancer—most people don’t take it

First FDA-approved robot-assisted microsurgery for head-and-neck cancer performed at Cedars-Sinai

Nivolumab demonstrates superiority over standard of care for head-and-neck cancer in phase III trial

Never miss an issue!

Login

Survey reveals most Americans are uninformed about HPV
A vaccine can prevent cancer—most people don’t take it